Similar Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS, Myfortic) Compared With Mycophenolate Mofetil (MMF) in De Novo Heart Transplant Recipients: Results of a 12-Month, Single-blind, Randomized, Parallel-group, Multicenter Study

Journal of Heart and Lung Transplantation

Volumn 25, Issue 8, 2006, Pages 935-941

  Kobashigawa, Jon A ^a   Renlund, Dale G ^b   Gerosa, Gino ^c   Almenar, Luis ^d   Eisen, Howard J ^e   Keogh, Anne M ^f   Lehmkuhl, Hans B ^g   Livi, Ugolino ^h   Ross, Heather ⁱ   Segovia, Javier ^j   Yonan, Nizar ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f ST VINCENT S HOSPITAL   (Australia)

^g DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^h Division of Medical Oncology   (Italy)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k WYTHENSHAWE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BENIGN TUMOR; BLOOD DISEASE; BREAST DISEASE; CARDIAC GRAFT REJECTION; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EAR DISEASE; ENDOCRINE DISEASE; ENTERIC COATED TABLET; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; GRAFT FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEPATOBILIARY DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INNER EAR DISEASE; KIDNEY DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MENTAL DISEASE; METABOLIC DISORDER; MICROEMULSION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN DISEASE; THROMBOCYTOPENIA; VASCULAR DISEASE; VOMITING;

ADOLESCENT; ADULT; AGED; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SINGLE-BLIND METHOD; TABLETS, ENTERIC-COATED; TIME FACTORS;

EID: 33746473566     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.04.005     Document Type: Article

References (20)

1. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
2. Allison A.C., and Eugui E.M. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136 (1993) 5-28
3. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507-515
4. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Drug Safety 24 (2001) 645-663
5. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200-205
6. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients. results of a 1-year study. Am J Transplant 4 (2004) 237-243
7. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231-236
8. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525
9. Hosenpud J.D., and Bennett L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization. an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 72 (2001) 1662-1665
10. Kirklin J.K., Bourge R.C., Naftel D.C., et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443). initial clinical experience. J Heart Lung Transplant 13 (1994) 444-450
11. Taylor D.O., Ensley R.D., Olsen S.L., Dunn D., and Renlund D.G. Mycophenolate mofetil (RS-61443). preclinical, clinical and three-year experience in heart transplantation. J Heart Lung Transplant 113 (1994) 571-582
12. Gregory C.R., Wang X., Pratt R.E., et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59 (1994) 655-661
13. Kobashigawa J.A. Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 13 (1998) 117-121
14. Rose M.L.D., Smith A., John D., et al. Mycophenolate mofetil (MMF) depresses antibody production after cardiac transplantation. Circulation 102 (2000) II-490
15. Weigel G., Griesmacher A., Darimi A., Zuckermann A.O., Grimm M., and Mueller M.M. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 21 (2002) 1074-1079
16. Richter M.H., Zahn S., Kraus M., Mohr F.W., and Olbrich H.G. Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model. comparative study with cyclosporine and FK 506. J Heart Lung Transplant 22 (2003) 1107-1116
17. Pethig K., Heublein B., Wahlers T., Dannenberg O., Oppelt P., and Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy. influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 23 (2004) 61-66
18. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the International Society for Heart and Lung Transplantation. nineteenth official report-2002. J Heart Lung Transplant 21 (2002) 950-970
19. Renlund D.G., Gopinathan S.K., Kfoury A.G., and Taylor D.O. Mycophenolate mofetil (MMF) in heart transplantation. rejection prevention and treatment. Clin Transplant 10 (1996) 136-139
20. Mardigyan V., Giannetti N., Cecere R., Besner J.G., and Cantarovich M. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 24 (2005) 1614-1618